Micropolis AI Robotics Files 424B3 Prospectus Supplement

TL;DR

**Micropolis AI Robotics just filed a prospectus, likely gearing up to sell more stock.**

AI Summary

Micropolis AI Robotics filed a 424B3 prospectus supplement on March 24, 2026, detailing a new offering under their existing registration statement (File No. 333-290424). This filing indicates the company is likely raising capital, which could dilute existing shareholders if new shares are issued, but also provides funds for growth initiatives in AI Robotics. Investors should monitor the specifics of this offering to understand its impact on share value and future company plans.

Why It Matters

This filing signals Micropolis AI Robotics is preparing to raise capital, which could fund expansion but also potentially dilute current shareholders.

Risk Assessment

Risk Level: medium — The filing of a prospectus supplement often precedes a capital raise, which can lead to share dilution for existing investors.

Analyst Insight

Investors should look for subsequent filings (like a pricing supplement or 424B5) to understand the specific terms (e.g., number of shares, price) of the offering and assess potential dilution or growth opportunities.

Key Numbers

• 424B3 — Form Type (Indicates a prospectus supplement for an offering)
• 0001213900-26-033193 — SEC Accession No. (Unique identifier for this specific filing)
• 2026-03-24 — Filing Date (Date the prospectus supplement was filed)

Key Players & Entities

• Micropolis AI Robotics (company) — Filer of the 424B3 prospectus supplement
• 0001993431 (person) — CIK of Micropolis AI Robotics
• 2026-03-24 (date) — Filing Date of the 424B3
• 333-290424 (person) — File Number for the registration statement

FAQ

Key Financial Figures

• $2.91 — rdinary shares on the NYSE American was $2.91 per share. Investing in our securities
• $5.00 — e price of the warrant was reduced from $5.00 per share to $2.75 per share, subject t
• $2.75 — ant was reduced from $5.00 per share to $2.75 per share, subject to any adjustments p

Filing Documents

• ea0282984-424b3_micropolis.htm (424B3) — 19KB
• 0001213900-26-033193.txt ( ) — 20KB

Use of Proceeds

Use of Proceeds We will not receive any proceeds from the sale of ordinary shares by the Selling Shareholder pursuant to the Prospectus or this Prospectus Supplement. We may receive gross proceeds from the cash exercise of the warrant, as amended, equal to the product of (i) the number of Amended Warrant Shares actually issued upon exercise of the warrant, and (ii) the exercise price of $2.75 per share (subject to adjustment), to the extent the warrant is exercised for cash rather than on a cashless basis. We intend to use any such proceeds for general corporate purposes, which may include working capital, capital expenditures, research and development, and potential strategic transactions. Plan of Distribution The Plan of Distribution section in the Prospectus continues to describe the general manner in which the Selling Shareholder may dispose of the Registrable Securities from time to time. This Prospectus Supplement does not change the identity of the Selling Shareholder or the methods by which the Selling Shareholder may sell the securities covered by the registration statement. From and after the date of this Prospectus Supplement, references in the Plan of Distribution and elsewhere in the Prospectus to the warrant and the warrant shares should be read to take into account the Warrant Amendment, including the reduced number of Amended Warrant Shares and the revised warrant exercise price. No Other Changes to the Prospectus Except as specifically set forth in this Prospectus Supplement, the information set forth in the Prospectus remains unchanged and in full force and effect. This Prospectus Supplement is not complete without, and may not be delivered or used except in connection with, the Prospectus and any other prospectus supplements relating thereto. You should rely only on the information contained in or incorporated by reference into the Prospectus, this Prospectus Supplement, and any additional prospectus supplements or amendments that we ma

View Full Filing

View this 424B3 filing on SEC EDGAR